Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection (Anascorp)
Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection is an FDA-licensed reference biologic from Rare Disease Therapeutics, Inc. (RDT). Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2011
Reference approved
Reference product
Anascorp Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection
Rare Disease Therapeutics, Inc. (RDT)
- Approved
- Aug 03, 2011
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection, in chronological order.
Reference approval
Approval date of the reference Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection product.
15 yr 1 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
7 yr 11 mo ago
Frequently asked questions
Are there biosimilars approved for Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection (Anascorp)?
No 351(k) biosimilars or interchangeable biosimilars referencing Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.